Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,756
datasets available to search
ShareScore release 0.9.0
Dataset results
2,756 results for “Head and neck”
PD1+CD8+ cells are an independent prognostic marker in patients with head and neck cancer
<p><strong>Data open:</strong> file with parametres used for the multivariate evaluation. </p>
Serum aminoacid levels in patients with spinocelular cancer of head and neck: anonymized dataset
<p><strong>Dataset containing analysis of free serum amino acid concentrations in patients with head and neck spinocellular tumors.</strong></p> <p>The study was conducted in accord with the Helsinki Declaration of 1964 and all subsequent revisions thereof. It was approved by the ethical committee of St. Anne’s Faculty Hospital, Brno, and by ethical committee of University Hospital Motol, Prague, Czech Republic.</p> <p>All blood samples were obtained from HNSCC patients who developed histologically verified primary HNSCC after they signed the informed consent. Blood samples were obtained by venipuncture. The blood samples were centrifuged at 3000 rpm at 4°C for 10 min within 60 min after collection. Serum was aliquoted and stored at −80°C until analysis.</p> <p>The inclusion criteria were: age 40-95 years; no prior chemotherapy; no endocrinologic or metabolic disorders; no uncontrolled hypertension or infections; normal liver, heart and kidney function; and adequate bone marrow reserve.</p> <p>Amino acid profiles were examined using ion-exchange liquid chromatography (AAA-400, Ingos, Prague, Czech Republic) with post-column derivatization by ninhydrin and absorbance detector in visible light range (IEC-Vis).</p>
HaN-Seg: The head and neck organ-at-risk CT & MR segmentation dataset
<p><strong>The HaN-Seg: Head and Neck Organ-at-Risk CT & MR Segmentation Dataset</strong> is a publicly available dataset of anonymized head and neck (HaN) images of 42 patients that underwent both CT and T1-weighted MR imaging for the purpose of image-guided radiotherapy planning. In addition, the dataset also contains reference segmentations of 30 organs-at-risk (OARs) for CT images in the form of binary segmentation masks, which were obtained by curating manual pixel-wise expert image annotations. A full description of the HaN-Seg dataset can be found in:</p> <p>G. Podobnik, P. Strojan, P. Peterlin, B. Ibragimov, T. Vrtovec, "HaN-Seg: The head and neck organ-at-risk CT & MR segmentation dataset", Medical Physics, 2023. <a href="https://doi.org/10.1002/mp.16197" target="_blank" rel="noopener">10.1002/mp.16197</a>,</p> <p>and any research originating from its usage is required to cite this paper.</p> <p>In parallel with the release of the dataset, the <strong><a href="https://han-seg2023.grand-challenge.org">HaN-Seg: The Head and Neck Organ-at-Risk CT & MR Segmentation Challenge</a></strong> is launched to promote the development of new and application of existing state-of-the-art fully automated techniques for OAR segmentation in the HaN region from CT images that exploit the information of multiple imaging modalities, in this case from CT and MR images. The task of the HaN-Seg challenge is to automatically segment up to 30 OARs in the HaN region from CT images in the devised test set, consisting of 14 CT and MR images of the same patients, given the availability of the training set (i.e. the herein publicly available HaN-Seg dataset), consisting of 42 CT and MR images of the same patients with reference 3D OAR binary segmentation masks for CT images.<br><br>Please find below a list of relevant publications that address: (1) the assessment of inter-observer and inter-modality variability in OAR contouring, (2) results of the HaN-Seg challenge, (3) development of our multimodal segmentation model, and (4) development of MR-to-CT image-to-image translation using diffusion models:</p> <ol> <li>G. Podobnik, B. Ibragimov, P. Strojan, P. Peterlin, T. Vrtovec, "vOARiability: Interobserver and intermodality variability analysis in OAR contouring from head and neck CT and MR images", Medical Physics, 2024. <a href="https://doi.org/10.1002/mp.16924" target="_blank" rel="noopener">10.1002/mp.16924</a>,</li> <li>G. Podobnik, B. Ibragimov, E. Tappeiner, et al., "HaN-Seg: The head and neck organ-at-risk CT and MR segmentation challenge", Radiotherapy and Oncology, 2024. <a href="https://doi.org/10.1016/j.radonc.2024.110410" target="_blank" rel="noopener">10.1016/j.radonc.2024.110410</a>,</li> <li>G. Podobnik, P. Strojan, P. Peterlin, B. Ibragimov, T. Vrtovec, "Multimodal CT and MR Segmentation of Head and Neck Organs-at-Risk", MICCAI 2023, 2023. <a href="https://doi.org/10.1007/978-3-031-43901-8_71" target="_blank" rel="noopener">10.1007/978-3-031-43901-8_71</a>,</li> <li>R. M. Šter, G. Podobnik, T. Vrtovec, "Diffusion-based MR-to-CT translation of head and neck images", SPIE Medical Imaging 2025, 2025. <a href="https://doi.org/10.1117/12.3047458" target="_blank" rel="noopener">10.1117/12.3047458</a>.</li> </ol>
Data for: HPV upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer
<p>The membrane-associated RING-CH-type finger ubiquitin ligase MARCHF8 is a human homolog of the viral ubiquitin ligases Kaposi's sarcoma herpesvirus K3 and K5 that promote host immune evasion. Previous studies have shown that MARCHF8 ubiquitinates several immune receptors, such as the major histocompatibility complex II and CD86. While human papillomavirus (HPV) does not encode any ubiquitin ligase, the viral oncoproteins E6 and E7 are known to regulate host ubiquitin ligases. Here, we report that MARCHF8 expression is upregulated in HPV-positive head and neck cancer (HNC) patients but not in HPV-negative HNC patients compared to normal individuals. The MARCHF8 promoter is highly activated by HPV oncoprotein E6-induced MYC/MAX transcriptional activation. The knockdown of MARCHF8 expression in human HPV-positive HNC cells restores cell surface expression of the tumor necrosis factor receptor superfamily (TNFRSF) death receptors, FAS, TRAIL-R1, and TRAIL-R2, and enhances apoptosis. MARCHF8 protein directly interacts with and ubiquitinates the TNFRSF death receptors. Further, MARCHF8 knockout in mouse oral cancer cells expressing HPV16 E6 and E7 augments cancer cell apoptosis and suppresses tumor growth in vivo. Our findings suggest that HPV inhibits host cell apoptosis by upregulating MARCHF8 and degrading TNFRSF death receptors in HPV-positive HNC cells.</p>
Sarcopenia index predicts short-term prognosis of head and neck squamous cell carcinoma
<p>Dataset of "Sarcopenia index predicts short-term prognosis of head and neck squamous cell carcinoma"</p>
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT01104922. IPD Sharing: NO. Countries: 1. Publications: 1.
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT00798655. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
ClinicalTrials.gov study NCT04247282. IPD Sharing: YES. Countries: 1. Publications: 3.
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
ClinicalTrials.gov study NCT00736944. IPD Sharing: NO. Countries: 1. Publications: 10.
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
ClinicalTrials.gov study NCT00076310. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
ClinicalTrials.gov study NCT02926573. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
ClinicalTrials.gov study NCT01057589. IPD Sharing: Not stated. Countries: 6. Publications: 2.
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
ClinicalTrials.gov study NCT00833261. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
ClinicalTrials.gov study NCT06815705. IPD Sharing: YES. Countries: 1. Publications: 13.
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01195922. IPD Sharing: NO. Countries: 1. Publications: 3.
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
ClinicalTrials.gov study NCT02684253. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Symptom Burden in Head and Neck Cancer
ClinicalTrials.gov study NCT01219673. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
ClinicalTrials.gov study NCT02573259. IPD Sharing: NO. Countries: 7. Publications: 3.
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01218048. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
ClinicalTrials.gov study NCT00820248. IPD Sharing: NO. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.